With the passing of time, the skin ages with a slowdown in physiological cell mechanisms. Relaxation and thinning of the skin, together with the formation of wrinkles are the most obvious aspects of this process, directly linked to a steep reduction in hyaluronic acid in the extracellular matrix of the epithelium represented in the functional body parts and apparatus.

Beauty at its purest.

Hyaluronic acid does in fact play a crucial role as activator of biological cascades, besides stimulating cell migration and proliferation, in particular fibroblasts, and the production of collagen, which represent the main components of the skin matrix. Hyaluronic acid regulates the skin’s immune surveillance through specific interaction with its receptors.

Against the signs of passing time.

Thanks to its properties, topical skin formulations containing hyaluronic acid have quickly gained ample consensus in the field of aesthetic medicine and in the dermatological sector. Besides being used as a skin inductor to heal wounds, hyaluronic acid has been purposely introduced into specific intradermal formulations (injectable HA) to combat the skin ageing process (e.g. face wrinkles, dryness and loss of elasticity) and restore normal skin functions, by means of simple and minimally invasive procedures.

Ultra chemistry, no thanks.

Nevertheless, hyaluronic acid in native form is quickly degraded by a specific enzyme, hyaluronidase, with the result of remaining stable in the derma for a few days only. To overcome the obstacle, numerous medical devices have been developed for dermatological use, all of which contain hyaluronic acid and most of which have been developed by means of a synthetic cross-linking chemical process able to improve stability, rigidity and elasticity, but with a price to pay in biological terms: alteration of the natural molecular structure of the HA. So much so that products for topical use or injectable products containing HA, used to restore the physiology and the hydration of the micro environment typical of young skin, have shown a truly considerable variability of effects according to the different physical and chemical characteristics which distinguish them.

The dermoaesthetic area.

Established in Switzerland in 1945, over the years IBSA has gained unique experience and skills in the pharmaceutical field. Experience which has also been applied to the development of medical devices for dermatology based on hyaluronic acid thanks to the setting up of a division dedicated specifically to dermoaesthetic – IBSA DERMA. Through scientific expertise, continuous research, technological development and a modern production process IBSA DERMA has become one of the leading pharmaceutical companies in the production of hyaluronic acid in dermoaesthetic applications.


In what is by now a vast but extremely homologated market, such as that of dermoaesthetic medicine, IBSA DERMA distinguishes itself because it controls the entire product life cycle, from the bio-fermentation production of the raw material to it being ready to use in pre-filled HA syringes. IBSA now offers a complete range of products developed around the Hydrolift® Actionconcept, an innovative approach aimed at counteracting the physiological reduction of hyaluronic acid in the tissue, restoring hydration, elasticity and skin tone. Hydrolift® Action is the expression of the synergic action derived from the use of selected hyaluronic acids, produced using patented IBSA technology, which, when used in a balanced way, create the conditions for preventing and contrasting the ageing process.

Extra-pure hyaluronic acid

IBSA hyaluronic acid is of “extra pure” grade, i.e., produced by means of a bio-fermentative process patented by Streptoccocus zooepidemicus, positioning itself at global level in the highest quality bracket in terms of purity and safety for the health of users. The hyaluronic acid produced by IBSA is distinguished by:

  • a high degree of purity, thanks to a purification process which ensures residual levels of proteins, nucleic acids, chlorides, heavy metals, ethanol and water much below the maximum limits set by the EU pharmacopoeia
  • a low dispersion index which measures the degree of high homogeneousness of the molecular weights used in the production process
  • high resistance to the heat treatments used in the sterilization process

IBSA global strategy

IBSA’s global strategic goal is to optimize active ingredients, whereby to develop innovative pharmaceutical solutions with greater therapeutic effectiveness and tolerability, able to improve the patient’s reaction to dermoaesthetic treatment in order to obtain a totally satisfactory therapeutic end result.